-15%

PrEP (Pre-Exposure Prophylaxis)

SKU : PrEP-30TAB

āļ‚āļēāļĒāđāļĨāđ‰āļ§ 0 āļŠāļīāđ‰āļ™

āļĒāļąāļ‡āđ„āļĄāđˆāļĄāļĩāļĢāļĩāļ§āļīāļ§

āļŋ3,500

āļŋ2,990

āļˆāļģāļ™āļ§āļ™

āļĄāļĩāļŠāļīāļ™āļ„āđ‰āļēāļ­āļĒāļđāđˆāđƒāļ™āļ„āļĨāļąāļ‡ 2 āļŠāļīāđ‰āļ™

āļ„āļģāļ­āļ˜āļīāļšāļēāļĒāļŠāļīāļ™āļ„āđ‰āļēāđāļšāļšāļĒāđˆāļ­

PrEP involves taking a daily pill to prevent HIV infection before potential exposure.
āļŦāļĄāļ§āļ”āļŦāļĄāļđāđˆ: medication
Product description

Pre-Exposure Prophylaxis (PrEP)

PrEP (Pre-Exposure Prophylaxis) is a medication regimen used by HIV-negative individuals to reduce their risk of acquiring HIV. It involves taking a daily pill that contains two antiretroviral drugs, tenofovir disoproxil fumarate and emtricitabine, which work together to prevent HIV from spreading in the body. When taken consistently, PrEP can significantly lower the chances of contracting HIV through sexual activity or injection drug use. It's a highly effective tool in HIV prevention for individuals at high risk of exposure.

Who Should Consider Taking PrEP?
PrEP should be considered by individuals who are HIV-negative but at high risk of contracting HIV.

PrEP is recommended for those who:

Have multiple or HIV-positive partners and engage in condomless sex.
Share injection drug equipment.
Are sexually active gay or bisexual men.
Engage in transactional sex or sex work.
Have had a recent sexually transmitted infection (STI).
Have a partner whose HIV status is unknown or who engages in high-risk behaviors.

Side Effects and Interactions
PrEP drugs may have some side effects such as nausea, diarrhea, headaches, fatigue, abdominal discomfort, dizziness, decreased appetite, and rare changes in bone density or kidney function if they are used for a long time. It is vital for individuals taking PrEP to report any concerns or adverse effects to their healthcare provider to ensure proper management and continued adherence to the medication regimen.

āļ„āļ°āđāļ™āļ™āđāļĨāļ°āļĢāļĩāļ§āļīāļ§āļŠāļīāļ™āļ„āđ‰āļē
āļĒāļąāļ‡āđ„āļĄāđˆāļĄāļĩāļ„āļ°āđāļ™āļ™āđāļĨāļ°āļĢāļĩāļ§āļīāļ§ āđ€āļ›āđ‡āļ™āļ„āļ™āđāļĢāļāļ—āļĩāđˆāđāļŠāļ”āļ‡āļ„āļ§āļēāļĄāļ„āļīāļ”āđ€āļŦāđ‡āļ™
āļŋ3,500

āļŋ2,990

This website use cookies for best user experience, to find out more you can go to our Privacy Policy and Cookies Policy, Set Cookies Accept All. āļ™āđ‚āļĒāļšāļēāļĒāļ„āļ§āļēāļĄāđ€āļ›āđ‡āļ™āļŠāđˆāļ§āļ™āļ•āļąāļ§ āđāļĨāļ° āļ™āđ‚āļĒāļšāļēāļĒāļ„āļļāļāļāļĩāđ‰